CD300a is an inhibitory receptor (IR) belonging to the immunoglobulin super-family expressed on several immune cells. It binds phosphatidylethanolamine (PE) and phosphatidylserine (PS), usually exposed on the outer leaflet of apoptotic or activated cells, thus strengthening the role of this receptor in inflammation. 1 We have previously described CD300a expression and inhibitory functions on human/murine mast cells (MCs), on eosinophils (Eos), the cardinal effector cells of allergy, and on human basophils. 2 Atopic dermatitis (AD), a chronic, predominantly Th2-driven inflammatory skin disease, is characterized by an impaired epidermal barrier, skin lesions, pruritus, and colonization of S aureus bacteria. 3